Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Can activated beta-catenin (ABV) be used as a marker to predict aggressive osteosarcoma and progression to metastatic disease?
FY 2021-22
Summary
Osteosarcoma is a rare primary bone tumor with a peak incidence in children and young adults. Metastatic spread is detected in about 20% of patients on presentation, typically in the lungs. Currently there are no specific laboratory tests to indicate whether a tumor may metastasize or become locally aggressive. The identification of such a test would allow for the early identification and intervention for patients presenting without obvious disease spread who may be at a high risk for progression. Previous projects by this group have looked at a potential role of the protein activated beta-catenin (ABC) in in vitro cell lines and have found a potential relationship between the amount of ABC in tumor cell nuclei and aggressive/metastatic osteosarcoma. The current proposal is to continue this work by carrying out a similar analysis in osteosarcoma samples obtained from the Children's Oncology Group (COG). If this study finds the same relationship between ABC levels in tumor samples and the presence of metastatic disease, this is a test that could be done on biopsy samples of osteosarcoma tumors at the time of diagnosis to identify patients at higher risk for disease spread. This may have a significant impact on the treatment and ongoing monitoring of these patients. Following analysis of the tumor samples, we will confirm our results by studying whether increasing the expression of ABC in a mouse model of osteosarcoma will increase tumor size and/or metastases compared to a mouse model of osteosarcoma with normal ABC levels.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466547
Name
Hinton Kristin
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Can activated beta-catenin (ABV) be used as a marker to predict aggressive osteosarcoma and progression to metastatic disease?
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Activated Beta-Catenin; Metastasis; Osteosarcoma; Prognostic Factor
Abstract
Osteosarcoma is a rare primary bone tumor with a peak incidence in children and young adults. Metastatic spread is detected in about 20% of patients on presentation, typically in the lungs. Currently there are no specific laboratory tests to indicate whether a tumor may metastasize or become locally aggressive. The identification of such a test would allow for the early identification and intervention for patients presenting without obvious disease spread who may be at a high risk for progression. Previous projects by this group have looked at a potential role of the protein activated beta-catenin (ABC) in in vitro cell lines and have found a potential relationship between the amount of ABC in tumor cell nuclei and aggressive/metastatic osteosarcoma. The current proposal is to continue this work by carrying out a similar analysis in osteosarcoma samples obtained from the Children's Oncology Group (COG). If this study finds the same relationship between ABC levels in tumor samples and the presence of metastatic disease, this is a test that could be done on biopsy samples of osteosarcoma tumors at the time of diagnosis to identify patients at higher risk for disease spread. This may have a significant impact on the treatment and ongoing monitoring of these patients. Following analysis of the tumor samples, we will confirm our results by studying whether increasing the expression of ABC in a mouse model of osteosarcoma will increase tumor size and/or metastases compared to a mouse model of osteosarcoma with normal ABC levels.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hinton, Kristin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~